Precigen begins clinical trial for HPV-positive tumors

By The Science Advisory Board staff writers

August 17, 2020 -- Precigen has dosed the first patients with Prgn-2009, an off-the-shelf investigational immunotherapy candidate, in a phase I/II clinical trial for the treatment of cancers associated with human papillomavirus (HPV).

The immunotherapy utilizes the company's UltraVector and AdenoVerse platforms targeting HPV solid tumors. The therapy uses gorilla adenovectors that have large payload capacities and the potential for repeat administration due to very low to no seroprevalence in the human population.

The phase I clinical study will use a 3+3 dose escalation to evaluate the safety of the drug as a monotherapy to determine dosage for the phase II study, followed by safety evaluation in combination with bintrafusp alfa (M7824), an investigational bifunctional fusion protein in patients with recurrent or metastatic HPV-associated cancers. The phase II study will evaluate Prgn-2009 as a monotherapy or in combination with bintrafusp alpha as a neoadjuvant or induction therapy in patients with stage II/III HPV16-positive oropharyngeal cancer.

The investigational immunotherapy is being developed in collaboration with the Center for Cancer Research and the U.S. National Cancer Institute.

Copyright © 2020

Create an Account

Already have an account? Sign in Here

To access all ScienceBoard content create a free account now:

Email Address:  

First Name:

Last Name:

Learn about ScienceBoard

Get the latest life sciences research and industry news, delivered straight to your inbox, for free.

Why subscribe?

ScienceBoard is uniquely focused on the business of research, addressing the biggest problems that the biomedical industry face. You’ll get breaking news, events coverage, and deep dives into the science that drives innovation, delivered to your inbox daily.

I have read and agree to the privacy policy and terms of service and wish to opt-in for

Email Preferences

Letter from the Editor Please send me twice-weekly roundups of all the latest life research and industry news.
SAB Announcements Please send me the latest announcements from The Science Advisory Board and their partners.
Spotlight Receive notifications about new content, services, or educational resources designed to help you sharpen your skills and grow professionally.